Background Heart transplantation (HT) is often the only viable treatment for patients with end-stage amyloid cardiomyopathy (ACM). Patients with cardiomyopathy due to transthyretin (ATTR) amyloidosis have abnormal transthyretin protein production in the liver. For these patients, combined heart-liver transplantation (HLT) has also been employed. We sought to examine the waitlist and post-transplantation outcomes of patients with ACM undergoing HT or HLT. Methods We queried the United Network for Organ Sharing (UNOS) registry for all adult patients (age ≥ 18 years) with amyloid cardiomyopathy listed for HT or HLT from 2008-2015. We then compared waitlist and post-transplantation outcomes among these patients. Results We identified 320 patients with ACM. Patients with ACM had higher cumulative hazards of waitlist mortality or delisting compared to patients with ischemic dilated cardiomyopathy or non-amyloid restrictive cardiomyopathy (p Conclusion Heart and heart-liver transplantation may be viable options for appropriately selected patients with amyloid cardiomyopathy, with similar waitlist and post-transplantation outcomes.